Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

It's uncertain whether the Biden administration proposal to cover obesity drugs in Medicare and Medicaid will survive ...

Antag Therapeutics thinks its glucose dependent insulinotropic polypeptide receptor (GIPR) antagonist could carve out a space ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Recent data from an Amgen obesity-drug trial only reinforced investors' impressions that Eli Lilly and Novo Nordisk have a prohibitive head start, thanks, in particular, to a new generation of Lilly ...

The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans ...

A new study finds people who take weight-loss drugs also cut back on alcohol consumption. Researchers think the drugs could ...

Several obesity experts said perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications.

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...